Medicus Pharma Ltd. has successfully closed its public offering, raising $7.0 million. The company issued 2,260,000 units at a price of $3.10 per unit, with each unit comprising one common share and one warrant to purchase an additional share. The warrants have an exercise price of $3.10 and will expire in five years. Maxim Group LLC served as the lead placement agent, with Brookline Capital Markets and D. Boral Capital as co-placement agents. The proceeds from the offering are intended to fund a Phase 2 clinical trial for basal cell carcinoma treatment using a dissolvable microarray needle skin patch, with potential expansion to other skin disease trials and general corporate purposes. The common shares are traded under the symbol "MDCX" on the Nasdaq Capital Market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.